Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018'; Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules.
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of auto reactive T-cells.
The report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018' outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 3, 5 and 1 respectively. Report covers products from therapy areas Immunology, Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Autoimmune Disorders, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Metastatic Breast Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Solid Tumor, Stroke and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018'; Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules.
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of auto reactive T-cells.
The report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018' outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 3, 5 and 1 respectively. Report covers products from therapy areas Immunology, Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Autoimmune Disorders, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Metastatic Breast Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Solid Tumor, Stroke and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
- The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
Alkermes Plc
Celgene Corp
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
ALKS-4230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APT-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-92252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daclizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Target NKG2D and IL2RA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDNA-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NARA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
Featured News & Press Releases
Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumors
Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
May 18, 2018: EMA review of Zinbryta confirms medicine’s risks outweigh its benefits
May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
Mar 09, 2018: EMA recommends immediate suspension and recall of s medicine Zinbryta
Mar 02, 2018: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis
Mar 02, 2018: EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders
Nov 10, 2017: EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage
Nov 08, 2017: Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer 32nd Annual Meeting
Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting
Oct 27, 2017: PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage
Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London
Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
Alkermes Plc
Celgene Corp
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
ALKS-4230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APT-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-92252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daclizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Target NKG2D and IL2RA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDNA-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NARA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
Featured News & Press Releases
Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumors
Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
May 18, 2018: EMA review of Zinbryta confirms medicine’s risks outweigh its benefits
May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
Mar 09, 2018: EMA recommends immediate suspension and recall of s medicine Zinbryta
Mar 02, 2018: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis
Mar 02, 2018: EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders
Nov 10, 2017: EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage
Nov 08, 2017: Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer 32nd Annual Meeting
Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting
Oct 27, 2017: PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage
Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London
Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Alkermes Plc, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Medicenna Therapeutics Corp, H2 2018
Pipeline by Nektar Therapeutics, H2 2018
Pipeline by Philogen SpA, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Alkermes Plc, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Medicenna Therapeutics Corp, H2 2018
Pipeline by Nektar Therapeutics, H2 2018
Pipeline by Philogen SpA, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Alkermes Plc
Celgene Corp
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Alkermes Plc
Celgene Corp
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
